In high-cholesterol (HC) and HFD-fed C57BL/6J mice, TRG restored hepatic cellular autophagy and reduced lipotoxicity to prevent steatosis by enhancing AMPK and reducing mTOR activity, showing a therapeutic effect against non-alcoholic fatty liver disease (NAFLD) [74]. The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatotic liver disease.